Targeting histone deacetylases for heart diseases

被引：8
作者：
Jin, Gang [1 ]
Wang, Kaiyue [1 ]
Zhao, Yaohui [1 ]
Yuan, Shuo [2 ]
He, Zhangxu [1 ]
Zhang, Jingyu [1 ]
机构：
[1] Henan Univ Chinese Med, Pharm Coll, Zhengzhou 450046, Peoples R China
[2] Zhengzhou Univ, Henan Childrens Hosp, Zhengzhou Childrens Hosp, Childrens Hosp, Zhengzhou 450018, Peoples R China
来源：
BIOORGANIC CHEMISTRY | 2023年 / 138卷
基金：
中国博士后科学基金;
关键词：
HDACs; Inhibitors; Heart diseases; ATTENUATES CARDIAC-HYPERTROPHY; CLASS-I; ANTITUMOR-ACTIVITY; ISCHEMIA/REPERFUSION INJURY; MINERALOCORTICOID RECEPTOR; BIOLOGICAL EVALUATION; ANTIFIBROTIC ACTIVITY; HDAC6; INHIBITOR; GENE-EXPRESSION; TRICHOSTATIN-A;
D O I：
10.1016/j.bioorg.2023.106601
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Histone deacetylases (HDACs) are responsible for the deacetylation of lysine residues in histone or non-histone substrates, leading to the regulation of many biological functions, such as gene transcription, translation and remodeling chromatin. Targeting HDACs for drug development is a promising way for human diseases, including cancers and heart diseases. In particular, numerous HDAC inhibitors have revealed potential clinical value for the treatment of cardiac diseases in recent years. In this review, we systematically summarize the therapeutic roles of HDAC inhibitors with different chemotypes on heart diseases. Additionally, we discuss the opportunities and challenges in developing HDAC inhibitors for the treatment of cardiac diseases.
引用
收藏
页数：12
相关论文
共 126 条
  • [1] Roles of cardiac transcription factors in cardiac hypertrophy
    Akazawa, H
    Komuro, I
    [J]. CIRCULATION RESEARCH, 2003, 92 (10) : 1079 - 1088
  • [2] Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors
    Antos, CL
    McKinsey, TA
    Dreitz, M
    Hollingsworth, LM
    Zhang, CL
    Schreiber, K
    Rindt, H
    Gorczynski, RJ
    Olson, EN
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (31) : 28930 - 28937
  • [3] Valproic Acid Is a Novel Activator of AMP-Activated Protein Kinase and Decreases Liver Mass, Hepatic Fat Accumulation, and Serum Glucose in Obese Mice
    Avery, Lindsay B.
    Bumpus, Namandje N.
    [J]. MOLECULAR PHARMACOLOGY, 2014, 85 (01) : 1 - 10
  • [4] CaM kinase II selectively signals to histone deacetylase 4 during cardiornyocyte hypertrophy
    Backs, Johannes
    Song, Kunhua
    Bezprozvannaya, Svetlana
    Chang, Shurong
    Olson, Eric N.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (07) : 1853 - 1864
  • [5] A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas
    Balasubramanian, S.
    Ramos, J.
    Luo, W.
    Sirisawad, M.
    Verner, E.
    Buggy, J. J.
    [J]. LEUKEMIA, 2008, 22 (05) : 1026 - 1034
  • [6] Rhein, a novel Histone Deacetylase (HDAC) inhibitor with antifibrotic potency in human myocardial fibrosis
    Barbosa, David Monteiro
    Fahlbusch, Pia
    de Wiza, Daniella Herzfeld
    Jacob, Sylvia
    Kettel, Ulrike
    Al-Hasani, Hadi
    Krueger, Martina
    Ouwens, D. Margriet
    Hartwig, Sonja
    Lehr, Stefan
    Kotzka, Jorg
    Knebel, Birgit
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [7] Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies
    Bhalla, KN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) : 3971 - 3993
  • [8] Class I HDAC inhibition stimulates cardiac protein SUMOylation through a post-translational mechanism
    Blakeslee, Weston W.
    Wysoczynski, Christina L.
    Fritz, Kristofer S.
    Nyborg, Jennifer K.
    Churchill, Mair E. A.
    McKinsey, Timothy A.
    [J]. CELLULAR SIGNALLING, 2014, 26 (12) : 2912 - 2920
  • [9] Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia
    Blum, Kristie A.
    Advani, Anjani
    Fernandez, Louis
    Van Der Jagt, Richard
    Brandwein, Joseph
    Kambhampati, Suman
    Kassis, Jeannine
    Davis, Melanie
    Bonfils, Claire
    Dubay, Marja
    Dumouchel, Julie
    Drouin, Michel
    Lucas, David M.
    Martell, Robert E.
    Byrd, John C.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (04) : 507 - 514
  • [10] Anticancer activities of histone deacetylase inhibitors
    Bolden, Jessica E.
    Peart, Melissa J.
    Johnstone, Ricky W.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) : 769 - 784
12345678910